1. [Long-Term Survival after Liver and Pulmonary Metastasectomy Following Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma-A Case Report].
- Author
-
Aizawa K, Takizawa K, Kawachi Y, Abe S, Ando T, Hirose Y, Ishikawa H, Sakata J, Muneoka Y, Kano Y, Tajima Y, Ichikawa H, Nakano M, Shimada Y, and Wakai T
- Subjects
- Male, Humans, Middle Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Gemcitabine, Metastasectomy, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms surgery, Adenocarcinoma, Liver Neoplasms drug therapy, Liver Neoplasms surgery
- Abstract
The patient was a 61-year-old man with a diagnosis of carcinoma of the pancreatic head. Abdominal computed tomography( CT)showed no distant metastasis, and he underwent subtotal stomach-preserving pancreatoduodenectomy. Immediately after surgery, he received liver perfusion chemotherapy with 5-fluorouracil followed by systemic gemcitabine. Eighteen months after surgery, CT revealed liver metastasis in the S6 segment, and partial hepatectomy was performed. The pathological diagnosis was liver metastasis of pancreatic cancer. Postoperatively, the patient was treated with gemcitabine and S-1 therapy for 1 year and then switched to S-1 monotherapy for about 6 months. Four years after the initial surgery, CT showed 2 metastases in the right lung. After 2 months of S-1 monotherapy, wedge resection of the upper and lower lobes of the right lung was performed. Gemcitabine and nab-paclitaxel therapy were administered, after the metastasectomy, but pleural dissemination appeared on CT 5 years after the initial surgery. Modified FOLFIRINOX therapy was started and continued for 8 months, but CT revealed further disseminated lesions in the diaphragm. Palliative irradiation was provided, but the disease gradually progressed. After multidisciplinary treatment, the patient survived for 6 years and 3 months after the initial surgery.
- Published
- 2024